A CNIC research finds a possible solution to improve the effectiveness of Vaccines against Covid

Vaccines against Covid-19 have been the fastest and most expected finding in the field of health so far as century. Now, an investigation of the National Card

A CNIC research finds a possible solution to improve the effectiveness of Vaccines against Covid

Vaccines against Covid-19 have been the fastest and most expected finding in the field of health so far as century. Now, an investigation of the National Cardiovascular Research Center (CNIC) seems to take another step to improve the effectiveness of these vaccines. It is an intranasal immunotherapy solution elaborated with dead bacteria and called MV130, which prevents mortality from SARS-COV-2 in animals and increases the immunogenicity of Vaccines against Covid.

In this work, collected by David Sancho, director of the CNIC Immunobiology Laboratory, and financed by Banco Santander through the Solidarity Fund together, Idipaz researchers and the CNB-CSIC have also participated. As explained by the Sancho, the MV130 "is a polybacterial preparation, developed by immunotek SL, which in previous clinical trials has been protected from recurrent respiratory infections when administered sublinguly," he says.

Now, the tests, carried out by Sancho and their group, with SARS-COV-2 in mice, have determined that the MV130 increases the effect of current vaccines against Covid. It is produced, says the CNIC researcher, "the enhancement of the immunogenicity of the vaccine: increase in response effector T lymphocytes T and increase in antibodies at the systemic level (IgG) and local (IGA)", aims. In addition, an intranasal pretreatment would reduce from 60% to 25% mortality by subsequent infection with COVID-19.

In summary, the MV130 "is supplied preventively against the infection (in the absence of vaccine, in the case that new variants appear that escape, or future new pathogens against which there is no vaccine), or Previously that vaccine (when it exists, as is the case) to enhance your immunogenicity, "clarifies Sancho.

Thus, this solution elaborated with dead bacteria (unlike many of traditional vaccines), would help the appearance of new variants of the virus, which reduce efficiency or escape the vaccine, or for future new pathogens for which There is still no vaccine. The compound, "By acting on the empowerment of innate immunity, is independent of the antigen; It does not affect the generation of new variants and theoretically could improve the innate response and immunogenicity of vaccines against any variant of this virus," he says The director of the CNIC immunobiology laboratory.

Regarding the population group that would benefit the use of MV130, once all the experimental phases have been completed, Sancho points out that, in principle, it would be to people who by age, diseases, treatments ..., they tend to have a bad response to the Vaccination. In the case of the COVID-19, immunodeficient people, older people ... ".

In any case, it defends "the high efficiency of current vaccines" against Covid and adds that "MV130 would be an optional treatment" for those particularly vulnerable people.

With this objective, as it consists of Sancho, "the immunotek laboratory, which develops the MV130, is already preparing an essay in humans to confirm our experimental results," he concludes.

Updated Date: 08 January 2022, 05:13

You need to login to comment.

Please register or login.

RELATED NEWS